# What are the steps in the de novo classification process?

hcco.app · November 13, 2026

> The de novo classification process begins when a sponsor identifies a low-to-moderate risk medical device that lacks a legally marketed predicate...

## Determining Predicate Device Eligibility

The de novo classification process begins when a sponsor identifies a low-to-moderate risk medical device that lacks a legally marketed predicate device. This pathway is essential for innovative technologies that do not meet the criteria for traditional 510(k) clearance. Sponsors must first submit a pre-submission to the FDA to discuss their regulatory strategy and gather feedback on proposed testing and clinical data requirements. This initial interaction helps clarify whether the de novo route is appropriate for the specific device classification and intended use, ensuring that the subsequent submission aligns with regulatory expectations.

**Also worth reading:** [How does the Texas Medicaid disability application process work?](https://hcco.app/knowledge/how_does_the_texas_medicaid_disability_application_process_work.php) · [How does TEFCA QHIN certification process impact healthcare cost-containment SaaS?](https://hcco.app/knowledge/how_does_tefca_qhin_certification_process_impact_healthcare_cost-containment_saas.php) · [What are the implementation costs for HCCO SaaS?](https://hcco.app/knowledge/what_are_the_implementation_costs_for_hcco_saas.php)

Once the regulatory strategy is confirmed, the sponsor prepares and submits a formal de novo request. This comprehensive document includes detailed device descriptions, intended use statements, and substantial evidence of safety and effectiveness. The evidence typically comprises valid scientific evidence from peer-reviewed literature and technical performance data, alongside clinical data if necessary. The FDA reviews the submission to determine if the device can be classified into Class II through appropriate special controls. Successful classification allows the device to serve as a predicate for future 510(k) submissions, facilitating broader market access for similar technologies while maintaining rigorous safety standards for patient care.

## Submitting Formal De Novo Request

The de novo classification process begins with the determination that a device is not substantially equivalent to a legally marketed predicate device. Manufacturers must first identify a suitable reference device to establish a valid basis for comparison. This critical step ensures that the new device’s intended use and technological characteristics are clearly defined against existing standards. Once the predicate is selected, the applicant prepares a comprehensive submission package. This documentation must include detailed technical specifications, bench testing results, and clinical data if necessary. The goal is to demonstrate reasonable assurance of safety and effectiveness through non-clinical methods or limited clinical investigations. Proper preparation at this stage minimizes potential delays and addresses regulatory concerns proactively.

After submission, the FDA conducts a thorough review of the de novo request. Reviewers evaluate the proposed classification and the supporting evidence to determine if the device qualifies for Class II regulation. If additional information is required, the agency may issue a request for additional information or a supplement. Upon successful review, the FDA grants de novo classification, establishing a new predicate for future similar devices. This outcome allows manufacturers to market the device commercially while providing a clear pathway for subsequent submissions. Understanding these procedural nuances is essential for navigating the regulatory landscape efficiently and ensuring timely market access for innovative medical technologies.

## FDA Review and Feedback Loop

The de novo classification process begins when a manufacturer submits a request to classify a novel medical device that lacks a legally marketed predicate. This pathway is specifically designed for low to moderate-risk devices that do not meet the criteria for 510(k) clearance. The submission must include comprehensive technical documentation, bench testing results, and clinical data demonstrating substantial equivalence to a reference device or, if none exists, a demonstration of safety and effectiveness through alternative means. The FDA reviews these materials to determine if the device can be classified into Class I or Class II based on its intended use and technological characteristics. This initial assessment is critical because it establishes the regulatory framework under which the device will operate, ensuring that appropriate controls are in place to mitigate potential risks to patients and users.

Following the initial review, the FDA may issue a request for additional information or clarification, creating a feedback loop that allows manufacturers to refine their submissions. Once the agency determines that the device meets the necessary standards, it grants de novo classification, thereby establishing a new predicate for future 510(k) submissions. This structured approach ensures that innovative healthcare technologies, such as those used in care coordination or surgical assistance, can reach the market efficiently while maintaining rigorous safety standards. For B2B healthcare platforms, understanding this pathway is essential for integrating compliant medical devices into broader operational workflows, ultimately enhancing cost containment and improving patient outcomes through validated technological solutions.

## Classification Decision Issuance

The de novo classification process initiates when a manufacturer determines that a novel medical device lacks a valid predicate through the traditional 510(k) pathway. This critical first step involves rigorous identification of the device’s intended use and technological characteristics. Manufacturers must then systematically search for any legally marketed devices that are substantially equivalent to their new product. When no such predicate exists, the applicant prepares a comprehensive de novo submission, which serves as the foundational document for regulatory review. This submission requires detailed descriptions of the device’s design, materials, and performance data. It also includes a proposed classification level and a justification for why the device is not classified as Class III. The preparation phase demands meticulous attention to regulatory standards, ensuring that all technical documentation aligns with current FDA guidelines. Manufacturers often engage in pre-submission meetings with the agency to clarify expectations and refine their approach before formal filing. This preparatory work is essential for establishing a clear regulatory pathway and minimizing potential delays during the subsequent review stages.

Once the de novo submission is filed, the FDA conducts a thorough scientific and regulatory evaluation. This review assesses whether the device poses a low to moderate risk, thereby qualifying for Class II classification. The agency examines clinical data, non-clinical testing results, and proposed labeling to ensure safety and effectiveness. If the FDA determines that the device meets the criteria for de novo classification, they issue a classification order. This order establishes the new device’s regulatory status and sets forth any special controls necessary to ensure safety. The issuance of this decision finalizes the de novo process, allowing the manufacturer to proceed with marketing the device in the United States. Subsequent steps may include post-market surveillance requirements or additional studies if specified in the classification order. This structured approach ensures that innovative medical technologies are properly evaluated while maintaining high standards for patient safety and regulatory compliance throughout the lifecycle of the device.

## Post-Approval Compliance Requirements

The de novo classification process initiates when a sponsor identifies a novel medical device lacking a valid predicate, necessitating a unique regulatory pathway. This first critical step involves conducting a comprehensive risk assessment to determine if the device qualifies as low or moderate risk. Sponsors must then compile a detailed submission package that includes substantial evidence of safety and effectiveness, often derived from clinical data or benchmarking against existing technologies. This documentation is submitted to the FDA for review, where regulatory experts evaluate whether the device meets the criteria for reclassification into Class II. The agency scrutinizes the proposed controls and specifications to ensure they adequately mitigate potential risks associated with the new technology, ensuring patient safety remains the paramount concern throughout this rigorous evaluation phase.

Following FDA acceptance, the review timeline typically spans several months, during which the agency may request additional information or clarification on technical specifications. Once the review is complete, the FDA issues a final decision granting de novo classification, thereby establishing the device as a new category of regulated medical products. Post-approval, the manufacturer must adhere to strict quality system regulations, including maintaining accurate records and implementing effective corrective actions. Continuous monitoring of post-market performance is essential to address any emerging safety issues promptly. This ongoing compliance ensures that the device continues to meet the initial safety standards that facilitated its successful classification, maintaining trust among healthcare providers and patients while supporting operational efficiency in cost-containment strategies.

## De Novo vs 510(k) Comparison

| Feature | De Novo | 510(k) |
| --- | --- | --- |
| Eligibility | Low-to-moderate risk, no predicate | Substantial equivalence to existing device |
| Predicate Requirement | None required | Must identify a valid predicate |
| Risk Level | Generally Class II | Class I or II |
| Review Focus | Safety, effectiveness, labeling | Comparison data and technical specs |

The De Novo classification pathway provides a vital route for novel medical devices lacking a suitable predicate. This process allows innovators to demonstrate safety and effectiveness through clinical data rather than comparative analysis. It is particularly valuable for emerging technologies that address unmet medical needs, enabling manufacturers to achieve FDA clearance efficiently while ensuring rigorous regulatory standards are met for patient safety.

## Quick answers

### What is the primary purpose of the de novo classification process?

The de novo process provides a pathway to classify low to moderate-risk devices that are substantially equivalent to a predicate but lack one.

### How long does the de novo review typically take?

The FDA aims to review de novo requests within 90 days, though total timeline depends on specific agency workload and information requests.

### Can a device be submitted via de novo if a predicate exists?

Yes, if the device is low to moderate risk and the existing predicate does not meet the definition of substantially equivalent.

### What happens after FDA grants de novo classification?

The device receives a new classification and becomes a predicate device for future 510(k) submissions.

Canonical: https://hcco.app/knowledge/what_are_the_steps_in_the_de_novo_classification_process.php
Markdown: https://hcco.app/knowledge/what_are_the_steps_in_the_de_novo_classification_process.php/index.md
